These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7906360)

  • 1. Compliance with iron-chelation treatment after bone marrow transplantation.
    Vreugdenhil G; Smeets M; Broekhuysen AM
    Lancet; 1994 Mar; 343(8897):604. PubMed ID: 7906360
    [No Abstract]   [Full Text] [Related]  

  • 2. Iron chelation.
    Chandy M
    J Assoc Physicians India; 1991 Sep; 39(9):665-6. PubMed ID: 1814896
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).
    Agarwal MB
    Indian J Pediatr; 1993; 60(4):509-16. PubMed ID: 8262587
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of thalassoemia--the current scenario.
    Datta S
    J Indian Med Assoc; 2002 Feb; 100(2):74-5. PubMed ID: 12206353
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.
    Olivieri NF; Koren G; St Louis P; Freedman MH; McClelland RA; Templeton DM
    Semin Hematol; 1990 Apr; 27(2):101-4. PubMed ID: 2190316
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
    Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
    Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
    Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alpha-ketohydroxypyridines.
    Kontoghiorghes GJ; Bartlett AN; Hoffbrand AV
    Prog Clin Biol Res; 1989; 309():107-14. PubMed ID: 2780745
    [No Abstract]   [Full Text] [Related]  

  • 9. An oral treatment for iron overload in thalassemia?
    Kowdley KV; Tavill AS
    Hepatology; 1996 Feb; 23(2):380-2. PubMed ID: 8591869
    [No Abstract]   [Full Text] [Related]  

  • 10. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Iron-chelating treatment].
    Vullo C; Di Palma A; De Sanctis V; Borgatti L; Atti G
    Haematologica; 1989 Oct; 74(5 Suppl):241-51. PubMed ID: 2512211
    [No Abstract]   [Full Text] [Related]  

  • 12. Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.
    Karakas Z; Yilmaz Y; Bayramoglu Z; Karaman S; Aydogdu S; Karagenc AO; Tugcu D; Dursun M
    Radiol Med; 2018 Aug; 123(8):572-576. PubMed ID: 29663188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
    Hatzipantelis ES; Karasmanis K; Perifanis V; Vlachaki E; Tziomalos K; Economou M
    Hemoglobin; 2014; 38(2):111-4. PubMed ID: 24351163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.
    Peng CT; Chang JS; Wang LY; Chiou SS; Hsiao CC; Wang SC; Hung GY; Wu KH
    Hemoglobin; 2009; 33(5):304-11. PubMed ID: 19814676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-thalassemia.
    Rund D; Rachmilewitz E
    N Engl J Med; 2005 Sep; 353(11):1135-46. PubMed ID: 16162884
    [No Abstract]   [Full Text] [Related]  

  • 17. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron-chelation therapy with oral deferiprone in patients with thalassemia major.
    Olivieri NF; Brittenham GM; Matsui D; Berkovitch M; Blendis LM; Cameron RG; McClelland RA; Liu PP; Templeton DM; Koren G
    N Engl J Med; 1995 Apr; 332(14):918-22. PubMed ID: 7877649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An orally active iron chelator.
    Nathan DG
    N Engl J Med; 1995 Apr; 332(14):953-4. PubMed ID: 7877655
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.